ArticleJournal of neuroimmunology2013

Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy.

Chulbul M Ahmed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.